Billy Beane, famously played by Brad Pitt in the movie Moneyball, didn’t help the Oakland A’s win by spending more. But by measuring differently. By using data to identify undervalued players, he built a competitive team without spending more.
Healthcare still operates by the old rules. Appointment volume, panel size, and throughput are treated as proxies for success. But these metrics say little about whether the right patients are receiving the right care at the right time, or whether scarce specialty resources are being deployed where they matter most.
When high-risk patients are missed, systems absorb downstream costs: emergency admissions, avoidable complications, leakage to outside providers, and lost opportunities for timely intervention.
AI allows organizations to surface patients currently hiding in plain sight within existing EHR data. This transforms patient identification from a passive, guideline-bound administrative task into a strategic weapon.
The sabermetrics of patient identification
Traditional identification methods are failing because they prioritize simplicity over precision.
Population-wide criteria cast a wide net, recklessly directing resources toward patients who are easy to reach rather than those who benefit most. The result is predictable: lower yield, massive waste, and specialty clinics choked with low-acuity visits that advance neither care nor margin.
AI-enabled population analysis applies a Moneyball lens to stop this inefficiency. It scans millions of data points already sitting in the EHR — labs, vitals, demographics, and histories — to surface patient profiles that demand immediate clinical review. It supports decision-making and integrates with workflows so operational teams can act without disruption.
This is accelerated precision at a population level. It equips clinicians with critical intelligence, making patient identification precise, scalable and economically efficient.
The clinical payoff
Organizations using advanced analytics to proactively surface patients who may benefit from follow-up are seeing measurable improvements across multiple disease areas. The value lies not in changing clinical practice, but in identifying the right patients earlier, before symptoms escalate and care becomes more invasive, costly and risky.
- Colorectal cancer: A study published in NEJM Catalyst found, targeted outreach informed by risk stratification has been associated with substantially higher diagnostic yield compared to untargeted screening campaigns.
- Liver disease: With metabolic dysfunction–associated liver disease affecting an estimated 30% of adults, reserchers from the National Institute of General Medical Sciences discovered earlier identification can reduce progression to cirrhosis and avoid high-cost complications.
- Arrhythmias: A significant portion of atrial fibrillation cases remain undiagnosed, exposing patients to preventable stroke risk. Studies by the JAMA Network estimate that AI-driven identification can support continuous monitoring and timely referral to cardiology before symptoms progress.
- Type 1 diabetes: Autoimmune diabetes is frequently misclassified, delaying appropriate treatment. Emerging research from the Journal of Diabetes suggests AI-enabled EHR analysis can help flag high-risk patients that might never have been tested under standard protocols.
Across these conditions, precision and earlier identification change the trajectory of care, while delay compounds clinical and financial risk.
The financial multiplier
For CFOs, the logic is undeniable. Earlier identification expands downstream revenue, cuts waste, and stabilizes high-value specialty service lines.
Consider the math in a hypothetical cohort of 100,000 adults aged 45 to 75. About one-third are overdue for CRC screening. By concentrating outreach on the specific 3 percent of patients surfaced through AI analysis, a health system identifies five times as many cancers and generates over $760,000 in incremental revenue over four years, all while paying for fewer overall screenings.
The same potential exists in liver disease, where early detection avoids late-stage complication costs while fueling hepatology and imaging. Cardiology benefits when arrhythmias are caught before stroke or heart failure. Endocrinology manages chronic conditions efficiently, preventing expensive emergencies.
This is Moneyball applied to the bottom line. We use data already on hand to reveal opportunities that traditional workflows blindly overlook. Over time, gains compound: Clinical teams capture higher diagnostic yield; operational teams integrate processes without added burden; finance teams secure stronger contribution margins and stop referral leakage.
These improvements create a unified path to margin growth grounded in data and aligned with clinical priorities.
The Moneyball advantage
AI adoption is accelerating, and the systems that win will be those that deploy it to simplify operations rather than disrupt them. Successful programs leverage existing EHR data and align with operational capacity. Every surfaced patient represents a clinical opportunity captured and a financial advantage secured.
The impact cuts across all payment models. Early identification improves value-based contract performance by preventing costly acute events. It strengthens fee-for-service margins by generating appropriate downstream volume. Crucially, it stops referral leakage by guiding patients to in-network specialty care before they seek services elsewhere.
Baseball changed when teams realized they were measuring the wrong things. Healthcare has reached that exact turning point. Full schedules and broad outreach look productive, but they are a mirage. Real value comes from using data to hunt for the patients who matter most: the ones whose care drives stronger outcomes and higher margins.
Systems that embrace this approach will outperform their peers, diagnose earlier, retain specialty care, and build financial resilience. Those that wait will watch competitors capture the value hidden inside their own data. In a landscape defined by thin margins, volume is a vanity metric. The differentiator is the ability to use data to elevate every clinical encounter.
That is how healthcare wins its Moneyball era.
Photo: JuSun, Getty Images
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
